Pawlenty joins RedPrairie board
ATLANTA — RedPrairie, a global supply chain and retail technology provider, on Tuesday announced the appointment of former Minnesota governor Tim Pawlenty to RedPrairie’s board of directors.
Pawlenty is the keynote speaker at the 13th Annual Drug Store News Industry Issue Summit on Nov. 29 in New York.
"Pawlenty’s experience in financial management and cultivating economic development makes him a strategic addition to RedPrairie’s existing board of tenured and innovative business leaders," the company stated.
"Tim’s combination of experience in the public and private sectors makes him an exceptional addition to RedPrairie’s board of directors," stated RedPrairie CEO and fellow board member Mike Mayoras. "Tim and RedPrairie share a track record of strong financial performance, a passion for innovation and a commitment to advancing the interests of those we serve."
"I’m impressed with RedPrairie’s visionary strategy," Pawlenty said. "Their unique position in this market, at the intersection of supply chain and all-channel commerce, is compelling. RedPrairie is at the forefront of the movement to connect the supply chain and consumers in this rapidly evolving global economy. I’m looking forward to being part of a company with such significant financial momentum and that is a force in driving change in the software industry."
During his time as governor of Minnesota, Pawlenty oversaw the interests of 5.2 million citizens and was responsible for a $50 billion biennial budget, 30,000 employees and more than 20 agencies and departments. As governor, Pawlenty oversaw economic development efforts on behalf of Minnesota businesses, including the promotion of international business through trade missions to nine countries.
Mylan settles with Warner Chilcott over generic version of Femcon Fe
PITTSBURGH — Generic drug maker Mylan has settled with Warner Chilcott in a case concerning an oral contraceptive.
Mylan said Wednesday that it and Famy Care had entered into an agreement with Warner Chilcott resolving a lawsuit over Femcon Fe (norethindrone and ethinyl estradiol chewable tablets, ferrous fumarate tablets).
Under the settlement, the litigation has been dismissed, and Mylan can begin marketing and selling a generic version of the drug once it receives approval from the Food and Drug Administration. Additional details of the settlement are confidential, Mylan said.
Mylan’s Matrix Labs subsidiary gets name change
PITTSBURGH — Mylan’s India-based subsidiary is changing its name, Mylan said Wednesday.
The generic drug maker announced that Matrix Labs, based in Hyderabad, India, had formally changed its name to Mylan Labs.
"We are pleased to complete the name change from Matrix to a Mylan company and are excited to operate in India under one powerful brand," Mylan chairman and CEO Robert Coury said.
Mylan acquired Matrix in 2006.